雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Kawaguchi T, Stahl EA, Kurreeman FA, Nishida N, Ohmiya H, Myouzen K, Takahashi M, Sawada T, Nishioka Y, Yukioka M, Matsubara T, Wakitani S, Teshima R, Tohma S, Takasugi K, Shimada K, Murasawa A, Honjo S, Matsuo K, Tanaka H, Tajima K, Suzuki T, Iwamoto T, Kawamura Y, Tanii H, Okazaki Y, Sasaki T, Gregersen PK, Padyukov L, Worthington J, Siminovitch KA, Lathrop M, Taniguchi A, Takahashi A, Tokunaga K, Kubo M, Nakamura Y, Kamatani N, Mimori T, Plenge RM, Yamanaka H, Momohara S, Yamada R, Matsuda F, Yamamoto K.	Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.	Nat Genet	44	511-6	2012
Terao C, Ikari K, Ohmura K, Suzuki T, Iwamoto T, Takasugi K, Saji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T.	Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01.	Ann Rheum Dis	71	1095-7	2012
Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, Shimada K, Murasawa A, Honjo S, Takasugi K, Matsuo K, Tajima K, Suzuki A, Yamamoto K, Momohara S, Yamanaka H, Yamada R, Saji H, Matsuda F, Mimori T.	A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects.	Ann Rheum Dis	70	2134-9	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki T, Ikari K, Kawaguchi Y, Yano K, Iwamoto T, Kawamoto M, Toyama Y, Taniguchi A, Yamanaka H, Momohara S.	Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients.	Mod Rheumatol		e-pub	2012
Shidara K, Inoue E, Hoshi D, Tanaka E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H.	The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients.	J Rheumatol	39	476-80	2012
Nakajima A, Inoue E, Shidara K, Hoshi D, Sato E, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H.	Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006.	Mod Rheumatol	21	594-7	2011

Ⅳ．研究成果の刊行物・別刷

Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population

Yukinori Okada[1–3,40], Chikashi Terao[4,5,40], Katsunori Ikari[6,40], Yuta Kochi[1,2,40], Koichiro Ohmura[5], Akari Suzuki[1], Takahisa Kawaguchi[4], Eli A Stahl[7,8], Fina A S Kurreeman[7–9], Nao Nishida[10], Hiroko Ohmiya[3], Keiko Myouzen[1], Meiko Takahashi[4], Tetsuji Sawada[11], Yuichi Nishioka[12], Masao Yukioka[13], Tsukasa Matsubara[14], Shigeyuki Wakitani[15], Ryota Teshima[16], Shigeto Tohma[17], Kiyoshi Takasugi[18], Kota Shimada[17], Akira Murasawa[19], Shigeru Honjo[20], Keitaro Matsuo[21], Hideo Tanaka[21], Kazuo Tajima[22], Taku Suzuki[6,23], Takuji Iwamoto[6,23], Yoshiya Kawamura[24], Hisashi Tanii[25], Yuji Okazaki[26], Tsukasa Sasaki[27], Peter K Gregersen[28], Leonid Padyukov[29], Jane Worthington[30], Katherine A Siminovitch[31], Mark Lathrop[32,33], Atsuo Taniguchi[6], Atsushi Takahashi[3], Katsushi Tokunaga[10], Michiaki Kubo[34], Yusuke Nakamura[35], Naoyuki Kamatani[36], Tsuneyo Mimori[5], Robert M Plenge[7,8], Hisashi Yamanaka[6], Shigeki Momohara[6,41], Ryo Yamada[37,41], Fumihiko Matsuda[4,38,39,41] & Kazuhiko Yamamoto[1,2,41]

© 2012 Nature America, Inc. All rights reserved.

Rheumatoid arthritis is a common autoimmune disease characterized by chronic inflammation. We report a meta-analysis of genome-wide association studies (GWAS) in a Japanese population including 4,074 individuals with rheumatoid arthritis (cases) and 16,891 controls, followed by a replication in 5,277 rheumatoid arthritis cases and 21,684 controls. Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of $P < 5.0 \times 10^{-8}$, including *B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4* and *PTPN2*. *ANXA3* was also associated with susceptibility to systemic lupus erythematosus ($P = 0.0040$), and *B3GNT2* and *ARID5B* were associated with Graves' disease ($P = 3.5 \times 10^{-4}$ and 2.9×10^{-4}, respectively). We conducted a multi-ancestry comparative analysis with a previous meta-analysis in individuals of European descent (5,539 rheumatoid arthritis cases and 20,169 controls). This provided evidence of shared genetic risks of rheumatoid arthritis between the populations.

Rheumatoid arthritis is a complex autoimmune disease characterized by inflammation and the destruction of synovial joints and affects up to 1% of the population worldwide. To date, more than 35 rheumatoid arthritis susceptibility loci, including *HLA-DRB1*, *PTPN22*, *PADI4*, *STAT4*, *TNFAIP3* and *CCR6*, among others, have been identified by GWAS in multiple populations[1–12] and by several meta-analyses of the original GWAS[13–16]. In particular, each meta-analysis of these GWAS uncovered a number of loci that were not identified in the single GWAS, leading to recognition of the enormous power of the meta-analysis approach for detecting causal genes in disease. However, these previous meta-analyses have been performed solely in European populations[13–16] and not in Asian ones. As multi-ancestry studies on validated rheumatoid arthritis susceptibility loci showed the existence of both population-specific and shared genetic components of rheumatoid arthritis[10,17], additional studies in Asian populations might provide useful insight into the underlying genetic architecture of rheumatoid arthritis, which would otherwise be difficult to capture using the studies in a single population. Here, we report a meta-analysis of GWAS and a replication study for rheumatoid arthritis in a Japanese population that was conducted by the Genetics and Allied research in Rheumatic diseases NETworking (GARNET) consortium[10,12]. We subsequently performed a multi-ancestry comparative analysis that incorporated results from a previously conducted meta-analysis of individuals of European ancestry[15].



Figure 1 Manhattan plots of the GWAS meta-analysis for rheumatoid arthritis in the Japanese population. The genetic loci that satisfied the genome-wide significance threshold of $P < 5.0 \times 10^{-8}$ (gray line) in the meta-analysis or in the combined study of the meta-analysis and the replication study are presented. The *y* axis shows the $-\log_{10} P$ values of the SNPs in the meta-analysis. The SNPs for which the *P* values were smaller than 1.0×10^{-15} are indicated at the upper limit of the plot.

A full list of author affiliations appears at the end of the paper.

Received 24 October 2011; accepted 1 March 2012; published online 25 March 2012; doi:10.1038/ng.2231

© 2012 Nature America, Inc. All rights reserved.

Table 1 Results of the GWAS meta-analysis and the replication studies for rheumatoid arthritis

					Associations in Japanese							Associations in Europeans[c]			
					GWAS meta-analysis			Replication study		Combined study		GWAS meta-analysis			
					Allele 1 freq.							Allele 1 Freq.			
rsID[a]	Chr.	Position (bp)	Cytoband	Gene(s)	Allele 1/2	RA	Control	OR (95% CI)[b]	*P*	OR (95% CI)[b]	*P*	OR (95% CI)[b]	*P*	RA	Control	OR (95% CI)[b]	*P*
SNPs with significant associations ($P < 5.0 \times 10^{-8}$ in the combined study)																	
rs11900673	2	62306165	2p15	*B3GNT2*	T/C	0.31	0.28	1.15 (1.08–1.21)	3.5×10^{-6}	1.09 (1.04–1.14)	6.0×10^{-4}	1.11 (1.07–1.15)	1.1×10^{-8}	0.13	0.13	1.05 (0.98–1.13)	0.17
rs2867461	4	79732239	4q21	*ANXA3*	A/G	0.46	0.44	1.13 (1.08–1.19)	4.7×10^{-6}	1.12 (1.08–1.17)	1.2×10^{-7}	1.13 (1.09–1.17)	1.2×10^{-12}	0.37	0.37	0.98 (0.92–1.04)	0.52
rs657075	5	131458017	5q31	*CSF2*	A/G	0.38	0.36	1.12 (1.06–1.18)	3.2×10^{-5}	1.11 (1.06–1.16)	3.8×10^{-6}	1.12 (1.08–1.15)	2.8×10^{-10}	0.10	0.10	1.04 (0.95–1.13)	0.37
rs12529514	6	14204637	6p23	*CD83*	C/T	0.16	0.14	1.19 (1.10–1.27)	6.8×10^{-6}	1.11 (1.05–1.18)	6.0×10^{-4}	1.14 (1.09–1.19)	2.0×10^{-8}	0.055	0.053	1.11 (0.99–1.24)	0.074
rs2233434	6	44340898	6p21.1	*NFKBIE*	G/A	0.24	0.21	1.23 (1.16–1.31)	9.2×10^{-11}	1.17 (1.11–1.23)	2.2×10^{-9}	1.19 (1.15–1.24)	5.8×10^{-19}	0.059	0.040	1.57 (1.11–2.21)	0.0099
rs10821944	10	63455095	10q21	*ARID5B*	G/T	0.39	0.36	1.17 (1.11–1.23)	1.0×10^{-8}	1.15 (1.10–1.20)	3.0×10^{-10}	1.16 (1.12–1.20)	5.5×10^{-18}	0.29	0.26	1.11 (1.05–1.17)	1.9×10^{-4}
rs3781913	11	72051144	11q13	*PDE2A-ARAP1*	T/G	0.71	0.69	1.11 (1.05–1.17)	3.2×10^{-4}	1.13 (1.08–1.18)	6.7×10^{-7}	1.12 (1.08–1.16)	5.8×10^{-10}	0.45	0.43	1.04 (0.99–1.09)	0.13
rs2841277	14	104462050	14q32	*PLD4*	T/C	0.72	0.69	1.11 (1.05–1.18)	2.8×10^{-4}	1.18 (1.13–1.24)	7.0×10^{-12}	1.15 (1.11–1.19)	1.9×10^{-14}	0.47	0.46	1.02 (0.96–1.09)	0.54
rs2847297	18	12787694	18p11	*PTPN2*	G/A	0.37	0.33	1.16 (1.11–1.23)	3.5×10^{-8}	1.06 (1.01–1.11)	0.013	1.10 (1.07–1.14)	2.2×10^{-8}	0.36	0.34	1.10 (1.05–1.15)	9.2×10^{-5}
SNPs with suggestive associations ($5.0 \times 10^{-8} \leq P < 5.0 \times 10^{-6}$ in the combined study)																	
rs4937362	11	127997949	11q24	*ETS1-FLI1*	T/C	0.71	0.68	1.13 (1.07–1.19)	2.0×10^{-5}	1.07 (1.02–1.12)	0.0061	1.09 (1.06–1.13)	7.5×10^{-7}	0.46	0.44	1.06 (1.01–1.11)	0.015
rs3783637	14	54417868	14q22	*GCH1*	C/T	0.76	0.74	1.13 (1.07–1.20)	6.5×10^{-5}	1.07 (1.02–1.13)	0.0062	1.10 (1.06–1.14)	2.0×10^{-6}	0.88	0.88	0.99 (0.88–1.11)	0.87
rs1957895	14	60978085	14q23	*PRKCH*	G/T	0.40	0.39	1.12 (1.06–1.18)	4.1×10^{-5}	1.07 (1.02–1.12)	0.0022	1.09 (1.05–1.13)	3.6×10^{-7}	0.093	0.089	1.01 (0.95–1.07)	0.73
rs6496667	15	88694672	15q26	*ZNF774*	A/C	0.38	0.35	1.13 (1.07–1.19)	4.7×10^{-5}	1.07 (1.02–1.11)	0.0050	1.09 (1.05–1.13)	1.4×10^{-6}	0.21	0.20	1.07 (1.01–1.13)	0.031
rs7404928	16	23796341	16p12	*PRKCB1*	T/C	0.65	0.62	1.13 (1.07–1.19)	1.5×10^{-5}	1.05 (1.01–1.10)	0.026	1.08 (1.05–1.12)	4.0×10^{-6}	0.75	0.75	1.01 (0.94–1.09)	0.79
rs2280381	16	84576134	16q24	*IRF8*	T/C	0.86	0.84	1.16 (1.08–1.25)	1.0×10^{-4}	1.09 (1.03–1.15)	0.0049	1.12 (1.07–1.17)	2.4×10^{-6}	0.62	0.60	1.05 (0.99–1.11)	0.081
SNPs in previously reported rheumatoid arthritis susceptibility loci ($P < 5.0 \times 10^{-8}$ in the GWAS)																	
rs766449	1	17547439	1p36	*PADI4*	T/C	0.44	0.40	1.17 (1.11–1.24)	4.6×10^{-8}	–	–	–	–	0.38	0.37	1.09 (1.03–1.05)	0.0022
rs2157337	6	32609122	6p21.3	*HLA-DRB1*	C/T	0.59	0.44	1.99 (1.88–2.11)	2.6×10^{-118}	–	–	–	–	0.69	0.46	2.50 (2.39–2.62)	$< 1.0 \times 10^{-300}$
rs6932056	6	138284130	6q23	*TNFAIP3*	C/T	0.092	0.073	1.35 (1.23–1.49)	3.2×10^{-9}	–	–	–	–	0.044	0.034	1.41 (1.24–1.60)	1.3×10^{-7}
rs1571878	6	167460832	6q27	*CCR6*	C/T	0.54	0.48	1.31 (1.24–1.39)	3.2×10^{-19}	–	–	–	–	0.47	0.43	1.13 (1.08–1.19)	5.9×10^{-7}

Chr., chromosome; Freq., frequency; RA, rheumatoid arthritis; OR, odds ratio; CI, confidence interval.
[a]SNPs with $P < 5.0 \times 10^{-6}$ in the combined study of the GWAS meta-analysis and the replication study or SNPs with $P < 5.0 \times 10^{-8}$ in the GWAS meta-analysis are annotated according to forward strand and NCBI Build 36.3. Full results of the replication study are provided in **Supplementary Table 3**. [b]Odds ratio of allele 1. [c]Associations in the previous meta-analysis in European populations[15].

The meta-analysis included 4,074 rheumatoid arthritis cases (with 81.4% and 80.4% of the subjects being positive for antibody to cyclic citrullinated peptide (anti-CCP) and rheumatoid factor, respectively) and 16,891 controls from three GWAS of Japanese subjects (from the BioBank Japan Project[10,18], Kyoto University[12] and the Institute of Rheumatology Rheumatoid Arthritis (IORRA)[19]; **Supplementary Table 1**). After the application of stringent quality control criteria, including principal-component analysis (PCA; **Supplementary Fig. 1**) for each GWAS, the meta-analysis was conducted by evaluating ~2.0 million autosomal SNPs with minor allele frequencies (MAFs) ≥0.01, which were obtained through whole-genome imputation of genotypes on the basis of the HapMap Phase 2 East Asian panels (Japanese in Tokyo (JPT) and Han Chinese in Beijing (CHB)). The inflation factor of the test statistics in the meta-analysis λ_{GC} was as low as 1.036, suggesting no substantial effects of population structure (**Supplementary Table 2**). The quantile-quantile plot of *P* values showed a marked discrepancy in the values in its tail from those anticipated under the null hypothesis that there is no association—even after removal of the SNPs located in the human leukocyte antigen (HLA) region, the major rheumatoid arthritis susceptibility locus—thereby showing the presence of significant associations in the meta-analysis (**Supplementary Fig. 2**).

We identified seven loci in the current meta-analysis that satisfied the genome-wide significance threshold of $P < 5.0 \times 10^{-8}$. These included previously known rheumatoid arthritis susceptibility loci, such as *PADI4* at 1p36, *HLA-DRB1* at 6p21.3, *TNFAIP3* at 6q23 and *CCR6* at 6q27 (refs. 1,3,6,10,15) (the smallest $P = 2.6 \times 10^{-118}$ was found at the *HLA-DRB1* locus; **Fig. 1** and **Table 1**). To our knowledge, the other three loci identified, *NFKBIE* at 6p21.1, *ARID5B* at 10q21 and *PTPN2* at 18p11, are newly associated ($P = 9.2 \times 10^{-11}$, 1.0×10^{-8} and 3.5×10^{-8}, respectively).

To validate the associations identified in the meta-analysis, we conducted a replication study of two independent Japanese rheumatoid arthritis case-control cohorts (cohort 1: 3,830 rheumatoid arthritis cases and 17,920 controls, cohort 2: 1,447 rheumatoid arthritis cases and 3,764 controls; **Supplementary Table 1**). To increase the number of subjects and enhance statistical power, genotype data obtained from other GWAS projects conducted for non-autoimmune diseases in Japanese using Illumina platforms were used for the replication control panels. For each of the 46 loci that exhibited $P < 5.0 \times 10^{-4}$ in



Figure 2 Regional plots of the loci newly associated with rheumatoid arthritis at the genome-wide significance threshold of $P < 5.0 \times 10^{-8}$ in the combined study of the meta-analysis and the replication study. (**a**–**i**) Regional plots are shown at *B3GNT2* (**a**), *ANXA3* (**b**), *CSF2* (**c**), *CD83* (**d**), *NFKBIE* (**e**), *ARID5B* (**f**), *PDE2A-ARAP1* (**g**), *PLD4* (**h**) and *PTPN2* (**i**). Diamonds represent the $-\log_{10} P$ values of the SNPs, and the red diamonds represent the $-\log_{10} P$ values of the SNPs in the meta-analysis. Red color for the smaller circles represents the r^2 value with the most significantly associated SNP (larger red circle). The purple circle represents the *P* value in the combined study. The blue line shows the recombination rates given by the HapMap Phase 2 east Asian populations (release 22). RefSeq genes at the loci are indicated below. Genes nearest to the marker SNPs at the loci are colored blue (**Supplementary Note**), and genes implicated in eQTL analysis are colored red (**Supplementary Table 4**). At 11q13, two genes (*PDE2A* and *ARAP1*) that are nearest to the SNP selected for the replication study and the most significant SNP in the meta-analysis are highlighted. The plots were drawn using SNP Annotation and Proxy Search (SNAP) version 2.2.

the meta-analysis and had not been reported as rheumatoid arthritis susceptibility loci[1–16], we selected a marker SNP for the replication study (Online Methods and **Supplementary Table 3**).

In the combined analyses of the meta-analysis and the replication study, including a total of 9,351 rheumatoid arthritis cases and 38,575 controls, we identified six newly associated loci, in addition to the *NFKBIE*, *ARID5B* and *PTPN2* loci, that satisfied the significance threshold of $P < 5.0 \times 10^{-8}$, including *B3GNT2* at 2p15, *ANXA3* at 4q21, *CSF2* at 5q31, *CD83* at 6p23, *PDE2A-ARAP1* at 11q13 and *PLD4* at 14q32 (**Figs. 1** and **2** and **Table 1**). Of these loci, *NFKBIE* had the smallest *P* value (5.8×10^{-19}). Although association with rheumatoid arthritis has been described for the *CSF2* and *PTPN2* loci[11,15,16,20,21], ours is the first report to our knowledge validating these associations with a threshold of $P < 5.0 \times 10^{-8}$. Suggestive associations were also observed in *ETS1-FLI1* at 11q24, *GCH1* at 14q22, *PRKCH* at 14q23, *ZNF774* at 15q26, *PRKCB1* at 16p12 and *IRF8* at 16q24 ($5.0 \times 10^{-8} \leq P < 5.0 \times 10^{-6}$). A summary of the genes in the newly associated loci and the results of *cis* expression quantitative trait locus (*cis* eQTL) analysis of the marker SNPs are provided (**Supplementary Table 4** and **Supplementary Note**).

Previous studies have reported associations of rheumatoid arthritis susceptibility loci with other autoimmune diseases[4,10,15,16]. Therefore, we assessed the association of these newly identified susceptibility loci with systemic lupus erythematosus (SLE) by examining the results of an SLE GWAS in the Japanese population (891 cases and 3,384 controls)[22] and in Graves' disease by genotyping 1,783 cases[10] (the controls from the SLE analysis were used for testing for Graves' disease). We observed significant associations of the *ANXA3* locus with SLE and of the *B3GNT2* and *ARID5B* loci with Graves' disease, which showed the same directional effects of the alleles as in rheumatoid arthritis ($P < 0.05/9 = 0.0056$, Bonferroni correction of the number of loci; **Supplementary Table 5**). It should be noted that relatively small sample sizes in the SLE and Graves' disease cohorts might yield limited statistical power, and further evaluations enrolling larger numbers of subjects would be desirable.

To highlight genetic backgrounds of rheumatoid arthritis that are common and divergent in different ancestry groups, we conducted a multi-ancestry comparative analysis of the present study in Japanese and a previous GWAS meta-analysis in Europeans that included 5,539 rheumatoid arthritis cases and 20,169 controls[15] (**Fig. 3a–c**). First, we compared associations in the reported[1–16] or newly identified rheumatoid arthritis susceptibility loci (**Fig. 3a** and **Supplementary Table 6**). Of the 46 rheumatoid arthritis risk variants evaluated, 6 were monomorphic in Japanese, and all were polymorphic in Europeans. We observed significant associations at 22 loci in Japanese and at 36 loci in Europeans (false discovery rate (FDR) < 0.05, $P < 0.0030$), with 14 loci being shared between the populations. Of the newly associated rheumatoid arthritis susceptibility loci identified in our Japanese meta-analysis, significant associations were also observed in the European meta-analysis at the *ARID5B* and *PTPN2* loci ($P = 1.9 \times 10^{-4}$ and 9.2×10^{-5}, respectively; **Table 1**). Significant positive correlation of odds ratios was observed between the studies ($r = 0.822$, $P = 8.1 \times 10^{-11}$; **Fig. 3b**), suggesting that a substantial proportion of genetic factors are shared between

© 2012 Nature America, Inc. All rights reserved.



Figure 3 Overlap of the associations with rheumatoid arthritis between Japanese and European populations. (**a**) Forest plots of SNPs in the rheumatoid arthritis susceptibility loci (**Supplementary Table 6**). We selected the genetic loci that have been validated to be associated with rheumatoid arthritis susceptibility by showing associations in the reports of multiple cohorts or satisfying the genome-wide significant threshold ($P < 5.0 \times 10^{-8}$) in previous studies, including in the meta-analysis and replication phases[1–16]. For each of the loci, the most significant SNP among those reported in the previous or present study were selected[1–16]. SNPs in the newly identified rheumatoid arthritis susceptibility loci are colored green. Odds ratios and 95% confidence interval (CI) values are based on rheumatoid arthritis risk alleles, and the SNPs are ordered according to the odds ratios in the Japanese study. Several SNPs were monomorphic in the Japanese population. The odds ratios of these SNPs in the European study are presented below. The asterisk indicates that an association of another variant at the *IRF5* locus was reported in the Japanese population[24]. (**b**) Correlation of the odds ratios of the SNPs in the validated rheumatoid arthritis susceptibility loci between the two populations. SNPs that were polymorphic in both populations were used; odds ratios were based on the minor allele in the Japanese population. (**c**) Correlation of the odds ratios of the genome-wide SNPs, excluding the rheumatoid arthritis susceptibility loci. Correlations were evaluated for sets of SNPs stratified by the thresholds based on the meta-analysis *P* values in each population after pruning of the SNPs by LD ($r^2 < 0.3$). Correlation coefficient and 95% CI are indicated on the *y* axis. Significant correlation of the odds ratios was observed (‡, $P < 0.005$), even for the SNPs that showed moderate associations with rheumatoid arthritis (meta-analysis $P < 0.4$ in each population).

the two ancestry groups[17]. When the rheumatoid arthritis cases of the Japanese GWAS meta-analysis were stratified into anti-CCP–positive or rheumatoid factor–positive cases ($n = 3{,}209$) and controls ($n = 16{,}891$), similar results were observed (data not shown). Nevertheless, most of the SNPs assessed here are not necessarily causal variants, and further fine mapping of the loci is warranted to precisely evaluate the shared genetic predisposition between the populations.

Next, we compared regional associations within each of the loci and identified unique patterns in the *ARID5B* locus at 10q21 (**Supplementary Fig. 3**). In Japanese, three peaks of association were observed ($P = 1.0 \times 10^{-8}$ at rs10821944, $P = 5.7 \times 10^{-8}$ at rs10740069 and $P = 8.5 \times 10^{-6}$ at rs224311). These three variants were in weak linkage disequilibrium (LD) in Japanese ($r^2 < 0.10$), indicating independent associations with each of the other SNPs that satisfied a region-wide significance threshold of $P < 3.5 \times 10^{-5}$ (conditional $P = 4.3 \times 10^{-6}$, 1.7×10^{-5} and 1.8×10^{-5}, respectively) (**Supplementary Fig. 3**). In contrast, there was only one peak of association in Europeans ($P = 1.2 \times 10^{-6}$ at rs12764378; $r^2 = 0.59$ with rs10821944 in Europeans), and no additional association was observed in conditional analysis with rs12764378 (the smallest conditional $P = 2.2 \times 10^{-4}$), suggesting that the number of independent associations may be different at this locus in the two populations.

Finally, we conducted polygenic assessment for common variants showing modest associations to rheumatoid arthritis (those not meeting the genome-wide association threshold). This approach has been recognized to be a means to explain a substantial proportion of genetic risk[23]. For the SNPs that were shared between the two meta-analyses but not included in the validated rheumatoid arthritis susceptibility loci, we adopted LD pruning of the SNPs ($r^2 < 0.3$). We then evaluated the correlation of odds ratios of the SNPs between the two meta-analyses and observed a significant positive correlation ($r = 0.023$, $P < 1.0 \times 10^{-300}$). When the SNPs were stratified according to the *P* values in each meta-analysis, significant positive correlations of odds ratios were observed for the SNPs, even for those showing modest association ($P < 0.4$ in the meta-analysis of Japanese or Europeans; $r = 0.014$–0.36 for each *P* value range, $P < 0.005$ for each correlation test) (**Fig. 3c**). Correlations (r) of odds ratios observed herein suggest substantial overlap of the genetic risk of rheumatoid arthritis between the two populations, not only in the validated rheumatoid arthritis susceptibility loci but also at the loci showing nonsignificant associations. This suggests the usefulness of a meta-analysis approach involving multiple ancestry groups in identifying additional susceptibility loci.

In summary, we identified multiple new loci associated with rheumatoid arthritis through a large-scale meta-analysis of GWAS in Japanese. Multi-ancestry comparative analysis provided evidence of significant overlap in the genetic risks of rheumatoid arthritis between Japanese and Europeans. Thus, findings from the present study should contribute to the further understanding of the etiology of rheumatoid arthritis.

URLs. GARNET consortium, http://www.twmu.ac.jp/IOR/garnet/home.html; The BioBank Japan Project (in Japanese), http://biobankjp.org/; International HapMap Project, http://www.hapmap.org/; PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/; EIGENSTRAT, http://genepath.med.harvard.edu/~reich/Software.htm; MACH and mach2dat, http://www.sph.umich.edu/csg/abecasis/MACH/index.

© 2012 Nature America, Inc. All rights reserved.

html; R statistical software, http://cran.r-project.org/; SNAP, http://www.broadinstitute.org/mpg/snap/index.php; NCBI GEO database, http://www.ncbi.nlm.nih.gov/geo/.

METHODS

Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

The authors acknowledge the essential role of the GARNET consortium in developing the study. In this study, the following GARNET members are included: CGM of RIKEN, University of Tokyo, the BioBank Japan Project, Kyoto University and IORRA. We would like to thank all the doctors and staff who participated in sample collection for the RIKEN cohort and the BioBank Japan Project. We thank K. Kobayashi and M. Kitazato for their technical assistance. We thank T. Raj for calculation of composite of multiple signals (CMS). We thank M. Kokubo for DNA extraction, GWAS genotyping and secretarial assistance. We would also like to thank H. Yoshifuji, N. Yukawa, D. Kawabata, T. Nojima, T. Usui and T. Fujii for collecting DNA samples. We thank Y. Katagiri for her technical efforts. We also appreciate the contribution of E. Inoue and other members of the Institute of Rheumatology, Tokyo Women's Medical University, for their efforts on the IORRA cohort. This study was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan, the Ministry of Health, Labour and Welfare (MHLW) in Japan, the Japan Society for the Promotion of Science (JSPS), Core Research for Evolutional Science and Technology (CREST), Solution-Oriented Research for Science and Technology (SORST), INSERM and the Okawa Foundation for Information and Telecommunications.

AUTHOR CONTRIBUTIONS

Y. Okada, C.T., K.I., Y. Kochi and K.O. designed the study and drafted the manuscript. Y. Okada, C.T., K.I., T.K., H.O., N.N., M.T., M.L., K. Tokunaga and M.K. managed genotyping and manipulation of GWAS data. Y. Okada, Y. Kochi, C.T. and K.I. managed genotyping of replication cohorts. Y. Okada, T.K., H.O., E.A.S., A. Takahashi and R.Y. performed statistical analysis. Y. Kochi, A.S., K. Myouzen, T. Sawada, Y. Nishoka, M.Y., T. Matsubara, S.W., R.T. and S.T. collected samples and managed phenotype data for the rheumatoid arthritis cohorts from the BioBank Japan Project and CGM, RIKEN. C.T., K.O., T.K., M.T., K. Takasugi, K.S., A.M., S.H., K. Matsuo, H. Tanaka, K. Tajima and M.L. collected samples and managed phenotype data for the rheumatoid arthritis cohorts from Kyoto University. K.I., T. Suzuki, T.I., Y. Kawamura, H. Tanii, Y. Okazaki and T. Sakaki collected samples and managed phenotype data for the rheumatoid arthritis cohorts from IORRA. Y. Kochi managed the data for the SLE and Graves' disease cohorts. A.S., C.T. and K.I. analyzed the sera of subjects with rheumatoid arthritis. E.A.S., F.A.S.K., P.K.G., J.W., K.A.S., L.P. and R.M.P. managed the data for the rheumatoid arthritis cohorts in European populations. A. Taniguchi, A. Takahashi, K. Tokunaga, M.K., Y. Nakamura, N.K., T. Minori, R.M.P., H.Y., S.M., R.Y., F.M. and K.Y. supervised the overall study.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at http://www.nature.com/naturegenetics/.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.

© 2012 Nature America, Inc. All rights reserved.

1. Suzuki, A. *et al.* Functional haplotypes of *PADI4*, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. *Nat. Genet.* **34**, 395–402 (2003).
2. Kochi, Y. *et al.* A functional variant in *FCRL3*, encoding Fc receptor–like 3, is associated with rheumatoid arthritis and several autoimmunities. *Nat. Genet.* **37**, 478–485 (2005).
3. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).
4. Remmers, E.F. *et al. STAT4* and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N. Engl. J. Med.* **357**, 977–986 (2007).
5. Plenge, R.M. *et al. TRAF1–C5* as a risk locus for rheumatoid arthritis—a genomewide study. *N. Engl. J. Med.* **357**, 1199–1209 (2007).
6. Plenge, R.M. *et al.* Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat. Genet.* **39**, 1477–1482 (2007).
7. Barton, A. *et al.* Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. *Nat. Genet.* **40**, 1156–1159 (2008).
8. Suzuki, A. *et al.* Functional SNPs in *CD244* increase the risk of rheumatoid arthritis in a Japanese population. *Nat. Genet.* **40**, 1224–1229 (2008).
9. Gregersen, P.K. *et al. REL*, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat. Genet.* **41**, 820–823 (2009).
10. Kochi, Y. *et al.* A regulatory variant in *CCR6* is associated with rheumatoid arthritis susceptibility. *Nat. Genet.* **42**, 515–519 (2010).
11. Freudenberg, J. *et al.* Genome-wide association study of rheumatoid arthritis in Koreans: population-specific loci as well as overlap with European susceptibility loci. *Arthritis Rheum.* **63**, 884–893 (2011).
12. Terao, C. *et al.* The human *AIRE* gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. *Hum. Mol. Genet.* **20**, 2680–2685 (2011).
13. Raychaudhuri, S. *et al.* Common variants at *CD40* and other loci confer risk of rheumatoid arthritis. *Nat. Genet.* **40**, 1216–1223 (2008).
14. Raychaudhuri, S. *et al.* Genetic variants at *CD28*, *PRDM1* and *CD2/CD58* are associated with rheumatoid arthritis risk. *Nat. Genet.* **41**, 1313–1318 (2009).
15. Stahl, E.A. *et al.* Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat. Genet.* **42**, 508–514 (2010).
16. Zhernakova, A. *et al.* Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. *PLoS Genet.* **7**, e1002004 (2011).
17. Kurreeman, F. *et al.* Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. *Am. J. Hum. Genet.* **88**, 57–69 (2011).
18. Nakamura, Y. The BioBank Japan Project. *Clin. Adv. Hematol. Oncol.* **5**, 696–697 (2007).
19. Yamanaka, H. *et al.* Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). *Mod. Rheumatol.* **17**, 98–105 (2007).
20. Yamada, R. *et al.* Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. *Am. J. Hum. Genet.* **68**, 674–685 (2001).
21. Tokuhiro, S. *et al.* An intronic SNP in a RUNX1 binding site of *SLC22A4*, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat. Genet.* **35**, 341–348 (2003).
22. Okada, Y. *et al.* A genome-wide association study identified *AFF1* as a susceptibility locus for systemic lupus eyrthematosus in Japanese. *PLoS Genet.* **8**, e1002455 (2012).
23. Stranger, B.E., Stahl, E.A. & Raj, T. Progress and promise of genome-wide association studies for human complex trait genetics. *Genetics* **187**, 367–383 (2011).
24. Shimane, K. *et al.* A single nucleotide polymorphism in the *IRF5* promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese patients. *Ann. Rheum. Dis.* **68**, 377–383 (2009).

[1]Laboratory for Autoimmune Diseases, Center for Genomic Medicine (CGM), RIKEN, Yokohama, Japan. [2]Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. [3]Laboratory for Statistical Analysis, CGM, RIKEN, Yokohama, Japan. [4]Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. [5]Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. [6]Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan. [7]Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. [8]Broad Institute, Cambridge, Massachusetts, USA. [9]Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. [10]Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. [11]Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan. [12]Yamanashi Prefectural Central Hospital, Yamanashi, Japan. [13]Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan. [14]Matsubara Mayflower Hospital, Hyogo, Japan. [15]Osaka Minami National Hospital, Osaka, Japan. [16]Department of Orthopedic Surgery, Tottori University, Tottori, Japan. [17]Department of Rheumatology, National Hospital Organization, Sagamihara Hospital, Kanagawa, Japan. [18]Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan. [19]Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan. [20]Saiseikai Takaoka Hospital, Toyama, Japan. [21]Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan. [22]Aichi Cancer Center Hospital and Research Institute, Aichi, Japan. [23]Department of Orthopaedic Surgery, Keio University, Tokyo, Japan. [24]Yokohama Clinic, Warakukai Medical Corporation, Yokohama, Japan. [25]Department of Psychiatry, Mie University School of Medicine, Mie, Japan. [26]Metropolitan Matsuzawa Hospital, Tokyo, Japan. [27]Graduate School of Education, University of Tokyo, Tokyo, Japan. [28]The Feinstein Institute for Medical Research, North Shore–Long Island Jewish Health System, Manhasset, New York, USA. [29]Rheumatology Unit,

Department of Medicine in Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. [30]Arthritis Research Campaign–Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. [31]Division of Medicine, University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, Ontario, Canada. [32]Commisariat a l'Energie Atomique (CEA), Institut Genomique, Centre National de Genotypage, Evry, France. [33]Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain, Paris, France. [34]Laboratory for Genotyping Development, CGM, RIKEN, Yokohama, Japan. [35]Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. [36]Laboratory for International Alliance, CGM, RIKEN, Yokohama, Japan. [37]Unit of Statistical Genetics, Center for Genomic Medicine Graduate School of Medicine Kyoto University, Kyoto, Japan. [38]Core Research for Evolutional Science and Technology (CREST) Program, Japan Science and Technology Agency, Kawaguchi, Japan. [39]Institut National de la Santé et de la Recherche Médicale (INSERM), Unité U852, Kyoto University Graduate School of Medicine, Kyoto, Japan. [40]These authors contributed equally to this work. [41]These authors jointly directed this work. Correspondence should be addressed to Y.K. (ykochi@src.riken.jp) or K.O. (ohmurako@kuhp.kyoto-u.ac.jp).

© 2012 Nature America, Inc. All rights reserved.

ONLINE METHODS

Subjects. The Japanese participants in the meta-analysis (4,074 rheumatoid arthritis cases and 16,891 controls) and the replication study (5,277 rheumatoid arthritis cases and 21,684 controls) were obtained through the collaborations of the GARNET consortium (**Supplementary Table 1**)[10,12]. The meta-analysis was conducted on three independent GWAS (from the BioBank Japan Project[18] with 2,414 rheumatoid arthritis cases and 14,245 controls[10], Kyoto University with 1,237 rheumatoid arthritis cases and 2,087 controls[12] and IORRA[19] with 423 rheumatoid arthritis cases and 559 controls). The replication study consisted of two independent cohorts (cohort 1 included 3,830 rheumatoid arthritis cases and 17,920 controls, and cohort 2 included 1,447 rheumatoid arthritis cases and 3,764 controls). We employed a case-control cohort of SLE (891 cases and 3,384 controls)[22] and 1,783 cases with Graves' disease[10]. Details of 5,539 rheumatoid arthritis cases and 20,169 controls included in the meta-analysis in European populations were described elsewhere[15]. All participants provided written informed consent for participation in the study, as approved by the ethical committees of the institutional review boards. Detailed descriptions of the participating subjects are provided (**Supplementary Note**).

Genotyping and quality control in the GWAS. Genotyping platforms and quality control criteria for the GWAS, including cutoff values for sample call rates, SNP call rates, MAF and Hardy-Weinberg *P* values, are given (**Supplementary Table 2**). For the subjects enrolled in each of three GWAS, we excluded closely related subjects with first- or second-degree kinship, which was estimated using PLINK version 1.06 (see URLs). We also excluded the subjects determined to be ancestry outliers from East Asian populations using PCA performed by EIGENSTRAT version 2.0 (see URLs) along with HapMap Phase 2 panels (release 24; **Supplementary Fig. 1**). Genotype imputation was performed on the basis of the HapMap Phase 2 East Asian populations, using MACH version 1.0.16 (see URLs) in a two-step procedure as described elsewhere[25]. We excluded imputed SNPs with MAF < 0.01 or *Rsq* < 0.5 from each of the GWAS. Associations of the SNPs with rheumatoid arthritis were assessed by logistic regression models assuming additive effects of the allele dosages of the SNPs using mach2dat software (see URLs).

Meta-analysis. We included 1,948,139 autosomal SNPs that satisfied quality control criteria in all three GWAS (**Supplementary Table 2**). SNP information was based on a forward strand of the NCBI build 36.3 reference sequence. The meta-analysis was performed using an inverse variance method assuming a fixed-effects model from the study-specific effect sizes (logarithm of odds ratio) and the standard errors of the coded alleles of the SNPs determined with the Java source code implemented by the authors[25]. Genomic control corrections[26] were carried out on test statistics of the GWAS using the study-specific inflation factor (λ_{GC}) and was applied or reapplied to the results of our current meta-analysis (**Supplementary Fig. 2**).

Replication study. We selected a SNP for the replication study from each of the loci that exhibited $P < 5.0 \times 10^{-4}$ in the meta-analysis that had not previously been reported as rheumatoid arthritis susceptibility loci[1–16] (**Supplementary Table 3**). For control subjects, we used genotype data obtained from additional GWAS for non-autoimmune diseases or healthy controls, genotyped using Illumina HumanHap550 BeadChips or HumanHap610-Quad BeadChips, and the cases for rheumatoid arthritis and Graves' disease were genotyped with the TaqMan genotyping system (Applied Biosystems; **Supplementary Table 1**). Selection of the SNP was conducted according to the following criteria: if the SNP with the most significant association in the locus was genotyped in the replication control panel, then that SNP was selected; otherwise, a tag SNP in the replication control panel with the strongest LD was selected (mean $r^2 = 0.89$). For the three SNPs that yielded low call rates (<90%), we alternatively selected proxy SNPs with the second strongest LD. As a result, average genotyping call rates of the SNPs were 99.9% and 99.0% for the controls and cases, respectively. We then evaluated concordance rates between the assayed genotypes by applying these two different methods to samples from 376 subjects who were randomly selected. This procedure yielded high concordance rates of ≥99.9%. Associations of the SNPs were evaluated using logistic regression assuming an additive-effects model of genotypes in R statistical software version 2.11.0 (see URLs). The combined study of the meta-analysis and replication study was performed using an inverse variance method assuming a fixed-effects model[25].

***Cis* eQTL analysis.** For each marker SNP of the newly identified rheumatoid arthritis susceptibility locus, correlations between SNP genotypes and expression levels of genes located 300 kb upstream or downstream of the SNP measured in B-lymphoblastoid cell lines (GSE6536) were evaluated using data from the HapMap Phase 2 east Asian populations[27].

Multi-ancestry analysis of the meta-analyses in Japanese and Europeans. We evaluated the associations of the variants in the validated rheumatoid arthritis susceptibility loci by comparing the results from the current meta-analysis in Japanese with those from a previous meta-analysis in Europeans[15]. We assessed two variants in the *IRF5* locus, where different causal variants were identified in the two populations[24]. For the conditional analysis of the regional associations in the *ARID5B* locus (**Supplementary Fig. 3**), we repeated the meta-analysis at that locus by incorporating genotypes of the referenced SNP(s) as additional covariate(s). For comparison of the odds ratios of the SNPs, we first selected SNPs that were shared between the meta-analyses in Japanese and Europeans. Next, we removed the SNPs located more than 1 Mb away from each of the marker SNPs in the validated rheumatoid arthritis susceptibility loci, except for in the HLA region, where we removed the SNPs located between 24,000,000 bp to 36,000,000 bp on chromosome 6 because of the existence of long-range haplotypes with rheumatoid arthritis susceptibility in this region[28]. LD pruning of the SNPs was conducted for the SNP pairs that were in LD ($r^2 \geq 0.3$) in both HapMap Phase 2 East Asian and Utah residents of Northern and Western European ancestry (CEU) populations (release 24). Correlations of the odds ratios were evaluated using R statistical software version 2.11.0.

25. Okada, Y. *et al.* Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. *PLoS Genet.* **7**, e1002067 (2011).
26. de Bakker, P.I. *et al.* Practical aspects of imputation-driven meta-analysis of genome-wide association studies. *Hum. Mol. Genet.* **17**, R122–R128 (2008).
27. Stranger, B.E. *et al.* Population genomics of human gene expression. *Nat. Genet.* **39**, 1217–1224 (2007).
28. Okada, Y. *et al.* Contribution of a haplotype in the HLA region to anti–cyclic citrullinated peptide antibody positivity in rheumatoid arthritis, independently of HLA-DRB1. *Arthritis Rheum.* **60**, 3582–3590 (2009).

© 2012 Nature America, Inc. All rights reserved.

Supplementary Information

Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population

Yukinori Okada, Chikashi Terao, Katsunori Ikari, Yuta Kochi, Koichiro Ohmura, Akari Suzuki, Takahisa Kawaguchi, Eli A. Stahl, Fina Kurreman, Nao Nishida, Hiroko Ohmiya, Keiko Myouzen, Meiko Takahashi, Tetsuji Sawada, Yuichi Nishioka, Masao Yukioka, Tsukasa Matsubara, Shigeyuki Wakitani, Ryota Teshima, Shigeto Tohma, Kiyoshi Takasugi, Kota Shimada, Akira Murasawa, Shigeru Honjo, Keitaro Matsuo, Hideo Tanaka, Kazuo Tajima, Taku Suzuki, Takuji Iwamoto, Yoshiya Kawamura, Hisashi Tanii, Yuji Okazaki, Tsukasa Sasaki, Peter K. Gregersen, Leonid Padyukov, Jane Worthington, Katherine A. Siminovitch, Mark Lathrop, Atsuo Taniguchi, Atsushi Takahashi, Katsushi Tokunaga, Michiaki Kubo, Yusuke Nakamura, Naoyuki Kamatani, Tsuneyo Mimori, Robert M. Plenge, Hisashi Yamanaka, Shigeki Momohara, Ryo Yamada, Fumihiko Matsuda, and Kazuhiko Yamamoto

*Correspondence authors: Yuta Kochi and Koichiro Ohmura

Yuta Kochi, MD, PhD

Laboratory for Autoimmune diseases, Center for Genomic Medicine, RIKEN

7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Telephone: +81-3-5800-8828, Fax: +81-3-5800-8828

E-mail: ykochi@src.riken.jp

Koichiro Ohmura, MD, PhD

Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto University

54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Telephone: +81-75-751-4380; Fax: +81-75-751-4338

Email: ohmurako@kuhp.kyoto-u.ac.jp

Supplementary Tables

Supplementary Figures

Supplementary Note

Supplementary Table 1. Characteristics of the cohorts enrolled in the study.

Disease	Stage	Cohort	Genotyping platform	No. subjects	Female	Age (mean±SD)	Auto-antibody positivity
Rheumatoid arthritis	GWAS meta-analysis	BioBank Japan Project	Illumina HumanHap610-Quad BeadChip	2,414	81.0%	61.5 ± 11.9	anti-CCP: 79.2%, RF: 75.7%
		Kyoto University	Illumina HumanHap300 BeadChip Illumina Human CNV370-Duo BeadChip Illumina HumanHap610-Quad BeadChip	1,237	80.1%	60.8 ± 12.2	anti-CCP: 85.2%, RF: 85.9%
		IORRA	Affymetrix Genome-wide Human SNP Array 6.0	423	81.3%	58.1 ± 12.1	anti-CCP: 86.6%, RF: 88.2%
	Replication study 1	BioBank Japan Project, RIKEN, IORRA	Taqman genotyping system	3,830	91.3%	60.6 ± 12.3	anti-CCP: 80.6%, RF: 86.3%
	Replication study 2	Kyoto University	Taqman genotyping system	1,447	82.1%	61.7 ± 12.6	anti-CCP: 82.9%, RF: 85.2%
Systemic lupus erythematosus	-	ADSG	Illumina HumanHap610-Quad BeadChip	891	88.1%	43.6 ± 13.9	-
Graves' disease	-	BioBank Japan Project	Taqman genotyping system	1,783	72.2%	48.6 ± 15.3	-
Control subjects	GWAS meta-analysis	BioBank Japan Project	Illumina HumanHap610-Quad BeadChip	14,245	44.3%	63.1 ± 12.2	-
		Kyoto University	Illumina HumanHap550 BeadChip Illumina HumanHap610-Quad BeadChip	2,087	44.4%	51.3 ± 15.3	-
		IORRA	Affymetrix Genome-wide Human SNP Array 6.0	559	61.2%	39.9 ± 10.9	-
	Replication study 1	BioBank Japan Project	Illumina HumanHap550 BeadChip Illumina HumanHap610-Quad BeadChip	17,920	48.0%	59.7 ± 14.2	-
	Replication study 2	Kyoto University	Illumina HumanHap550 BeadChip Illumina HumanHap610-Quad BeadChip	3,764	50.5%	57.2 ± 14.4	-

GWAS, genome-wide association study; SD, standard deviation; RF, rheumatoid factor; anti-CCP; anti-cyclic citrullinated peptide antibody.

Supplementary Table 2. Genotyping and imputation methods in the GWAS enrolled in the meta-analysis.

Cohort	No. subjects		GWAS QC criteria				Imputation method				No. SNPs after QC		Inflation factor
	RA cases	Controls	Sample call rate	SNP call rate	MAF[a]	HWE *P*-value[b]	Software	Reference	MAF	Quality score	GWAS	Imputed	
BioBank Japan Project	2,414	14,245	> 0.98	> 0.99	> 0.01	> 10^{-7}	MACH v1.0.16	HapMap Phase II (rel24), JPT+CHB	> 0.01	*Rsq* >0.5	477,784	2,263,308	1.061
Kyoto University	1,237	2,087	> 0.90[c]	> 0.95[c]	> 0.05	> 10^{-7}	MACH v1.0.16	HapMap Phase II (rel24), JPT+CHB	> 0.01	*Rsq* >0.5	228,622[d]	1,986,176	1.116
IORRA	423	559	> 0.95	> 0.98	> 0.05	> 10^{-6}	MACH v1.0.16	HapMap Phase II (rel24), JPT+CHB	> 0.01	*Rsq* >0.5	473,168	2,197,793	1.020
GWAS meta-analysis	4,074	16,891	-	-	-	-	-	-	-	-	-	1,948,139[e]	1.036

[a]Assessed in RA cases and controls, respectively.

[b]Assessed in controls.

[c]Assessed for each of the genotyping platforms, separately.

[d]SNPs that were shared among all the genotyping platforms were enrolled.

[e]SNPs that satisfied MAF > 0.01 and *Rsq* > 0.5 in all the GWAS were enrolled.

GWAS, genome-wide association study; QC, quality control; RA, rheumatoid arthritis; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.

Supplementary Table 3. Results of the replication study for the loci identified in the GWAS meta-analysis of rheumatoid arthritis.

rsID[a]	Chr	Position (bp)	Cyto-band	Gene(s)	Allele 1/2	GWAS meta-analysis				Replication study 1				Replication study 2				Combined study	
						Allele 1 Freq.		OR (95%CI)[b]	P	Allele 1 Freq.		OR (95%CI)[b]	P	Allele 1 Freq.		OR (95%CI)[b]	P	OR (95%CI)[b]	P
						RA	Control			RA	Control			RA	Control				
rs2236395	1	2,436,740	1p36	*TNFRSF14*	A/G	0.58	0.55	1.12 (1.06-1.18)	2.5E-05	0.56	0.55	1.06 (1.01-1.11)	2.9E-02	0.54	0.55	0.97 (0.89-1.06)	4.7E-01	1.07 (1.03-1.11)	6.3E-05
rs7519611	1	42,388,229	1p34	*GUCA2B*	T/C	0.60	0.58	1.12 (1.06-1.18)	7.1E-05	0.59	0.59	1.02 (0.97-1.07)	5.5E-01	0.58	0.58	1.01 (0.93-1.10)	8.1E-01	1.05 (1.02-1.09)	1.8E-03
rs4328027	1	54,689,944	1p32	*SSBP3*	C/T	0.69	0.67	1.14 (1.08-1.21)	5.4E-06	0.68	0.67	1.02 (0.97-1.08)	4.6E-01	0.68	0.66	1.09 (0.99-1.20)	7.2E-02	1.08 (1.04-1.12)	2.7E-05
rs4845624	1	150,094,437	1q21	*THEM5-THEM4*	G/A	0.42	0.40	1.10 (1.05-1.16)	2.9E-04	0.41	0.40	1.03 (0.98-1.08)	2.8E-01	0.40	0.40	1.01 (0.92-1.10)	9.0E-01	1.06 (1.02-1.09)	1.5E-03
rs11900673	2	62,306,165	2p15	*B3GNT2*	T/C	0.31	0.28	1.15 (1.08-1.21)	3.5E-06	0.31	0.29	1.10 (1.04-1.16)	7.1E-04	0.29	0.28	1.05 (0.95-1.15)	3.3E-01	1.11 (1.07-1.15)	1.1E-08
rs2418896	2	71,289,777	2p13	*PAIP2B-ZNF638*	G/A	0.23	0.22	1.14 (1.07-1.21)	5.8E-05	0.23	0.23	1.02 (0.96-1.09)	4.4E-01	0.22	0.21	1.08 (0.97-1.20)	1.5E-01	1.08 (1.04-1.12)	1.8E-04
rs1864548	2	79,543,080	2p12	*CTNNA2*	C/T	0.29	0.26	1.15 (1.09-1.22)	1.5E-06	0.29	0.28	1.01 (0.96-1.07)	6.0E-01	0.28	0.28	1.00 (0.91-1.10)	9.7E-01	1.07 (1.03-1.11)	3.7E-04
rs155399	3	1,361,467	3p26	*CNTN6*	C/T	0.21	0.19	1.14 (1.07-1.22)	7.4E-05	0.21	0.21	1.03 (0.97-1.10)	3.0E-01	0.21	0.21	1.02 (0.92-1.14)	7.0E-01	1.07 (1.03-1.12)	5.5E-04
rs4130687	3	29,419,115	3p24	*RBMS3*	G/A	0.12	0.10	1.20 (1.10-1.29)	2.2E-05	0.10	0.11	0.97 (0.90-1.06)	5.2E-01	0.10	0.10	1.01 (0.87-1.16)	9.4E-01	1.07 (1.01-1.13)	1.2E-02
rs2901755	3	173,167,209	3q26	*TMEM212-FNDC3B*	A/G	0.42	0.40	1.12 (1.06-1.18)	6.5E-05	0.42	0.41	1.04 (0.99-1.09)	1.6E-01	0.41	0.42	0.96 (0.88-1.04)	3.1E-01	1.06 (1.02-1.09)	1.5E-03
rs291928	3	175,210,677	3q26	*NLGN1*	A/G	0.08	0.07	1.22 (1.11-1.34)	8.3E-05	0.07	0.07	1.10 (1.00-1.21)	5.8E-02	0.06	0.06	1.00 (0.83-1.20)	9.9E-01	1.14 (1.07-1.21)	6.9E-05
rs17462424	4	47,293,055	4p12	*ATP10D-DORIN*	C/T	0.21	0.19	1.14 (1.07-1.22)	4.8E-05	0.19	0.19	0.98 (0.92-1.05)	5.8E-01	0.18	0.19	0.98 (0.88-1.09)	7.2E-01	1.05 (1.01-1.09)	2.2E-02
rs2867461	4	79,732,239	4q21	*ANXA3*	A/G	0.46	0.44	1.13 (1.08-1.19)	4.7E-06	0.47	0.45	1.12 (1.07-1.18)	5.4E-06	0.47	0.44	1.13 (1.04-1.23)	6.4E-03	1.13 (1.09-1.17)	1.2E-12
rs295208	5	94,347,865	5q15	*MCTP1*	T/C	0.38	0.36	1.12 (1.06-1.18)	4.0E-05	0.36	0.36	0.97 (0.93-1.03)	3.3E-01	0.37	0.37	0.99 (0.91-1.08)	8.4E-01	1.04 (1.00-1.07)	4.3E-02
rs657075	5	131,458,017	5q31	*CSF2*	A/G	0.38	0.36	1.12 (1.06-1.18)	3.2E-05	0.38	0.36	1.12 (1.06-1.18)	1.9E-05	0.37	0.35	1.09 (0.99-1.19)	6.8E-02	1.12 (1.08-1.15)	2.8E-10
rs9405675	6	389,600	6p25	*IRF4-EXOC2*	A/G	0.41	0.39	1.11 (1.05-1.17)	1.4E-04	0.40	0.39	1.02 (0.97-1.08)	3.8E-01	0.42	0.38	1.17 (1.07-1.27)	6.5E-04	1.08 (1.04-1.12)	9.6E-06
rs12529514	6	14,204,637	6p23	*CD83*	C/T	0.16	0.14	1.19 (1.10-1.27)	6.8E-06	0.16	0.15	1.10 (1.03-1.18)	5.0E-03	0.16	0.15	1.13 (1.00-1.27)	4.6E-02	1.14 (1.09-1.19)	2.0E-08
rs2233434	6	44,340,898	6p21.1	*NFKBIE*	G/A	0.24	0.21	1.23 (1.16-1.31)	9.2E-11	0.24	0.22	1.15 (1.08-1.21)	4.7E-06	0.25	0.21	1.23 (1.11-1.37)	5.1E-05	1.19 (1.15-1.24)	5.8E-19
rs725351	6	91,175,642	6q15	*MACH2-MAP3K7*	C/T	0.48	0.45	1.12 (1.06-1.17)	4.5E-05	0.46	0.45	1.02 (0.97-1.08)	3.6E-01	0.48	0.46	1.09 (1.00-1.18)	5.5E-02	1.07 (1.04-1.11)	4.7E-05
rs7752089	6	150,202,127	6q25	*LRP11*	A/G	0.30	0.27	1.14 (1.08-1.21)	8.6E-06	0.29	0.27	1.09 (1.03-1.15)	2.5E-03	0.26	0.28	0.89 (0.81-0.99)	2.4E-02	1.08 (1.04-1.12)	3.3E-05
rs10487790	7	15,009,432	7p21	*DGKB-TMEM195*	C/T	0.16	0.15	1.15 (1.07-1.23)	1.7E-04	0.16	0.15	1.04 (0.97-1.12)	2.3E-01	0.15	0.15	0.99 (0.88-1.12)	9.1E-01	1.08 (1.03-1.13)	1.1E-03
rs7808716	7	52,169,565	7p12	*LOC100131871*	G/A	0.56	0.54	1.12 (1.06-1.17)	4.4E-05	0.56	0.55	1.05 (1.00-1.10)	5.1E-02	0.56	0.55	1.04 (0.96-1.14)	3.3E-01	1.08 (1.04-1.11)	1.1E-05
rs4878117	9	89,475,284	9q21	*DAPK1*	C/T	0.53	0.51	1.10 (1.05-1.16)	2.8E-04	0.51	0.51	0.99 (0.95-1.04)	8.1E-01	0.50	0.51	0.97 (0.89-1.05)	4.4E-01	1.03 (1.00-1.07)	4.8E-02
rs1750734	10	11,201,984	10p14	*CUGBP2*	G/A	0.88	0.87	1.20 (1.10-1.30)	2.2E-05	0.87	0.86	1.06 (0.98-1.14)	1.4E-01	0.88	0.87	1.07 (0.94-1.22)	3.0E-01	1.11 (1.06-1.17)	3.2E-05
rs10821944	10	63,455,095	10q21	*ARID5B*	G/T	0.39	0.36	1.17 (1.11-1.23)	1.0E-08	0.40	0.36	1.15 (1.09-1.20)	1.5E-07	0.38	0.34	1.17 (1.07-1.28)	4.8E-04	1.16 (1.12-1.20)	5.5E-18
rs7911085	10	81,675,250	10q22	*MBL1P1-SFTPD*	A/G	0.26	0.23	1.17 (1.10-1.24)	9.9E-07	0.25	0.24	1.04 (0.98-1.10)	1.9E-01	0.24	0.24	0.96 (0.87-1.06)	4.1E-01	1.08 (1.04-1.12)	1.4E-04
rs7905501	10	94,830,706	10q23	*EXOC6-CYP26A1*	T/C	0.09	0.07	1.24 (1.13-1.36)	1.1E-05	0.08	0.08	0.96 (0.87-1.05)	3.8E-01	0.08	0.07	1.17 (1.00-1.37)	4.4E-02	1.10 (1.04-1.17)	1.3E-03
rs4255548	11	68,730,546	11q13	*MYEOV*	G/A	0.50	0.47	1.11 (1.06-1.17)	9.2E-05	0.47	0.47	1.00 (0.95-1.06)	8.9E-01	0.49	0.47	1.05 (0.96-1.15)	2.5E-01	1.05 (1.02-1.09)	1.8E-03
rs3781913	11	72,051,144	11q13	*PDE2A-ARAP1*	T/G	0.71	0.69	1.11 (1.05-1.17)	3.2E-04	0.72	0.69	1.12 (1.06-1.18)	4.6E-05	0.73	0.70	1.15 (1.05-1.27)	3.8E-03	1.12 (1.08-1.16)	5.8E-10
rs4937362	11	127,997,949	11q24	*ETS1-FLI1*	T/C	0.71	0.68	1.13 (1.07-1.19)	2.0E-05	0.69	0.68	1.06 (1.00-1.12)	4.0E-02	0.70	0.68	1.10 (1.00-1.21)	5.4E-02	1.09 (1.06-1.13)	7.5E-07
rs10876864	12	54,687,352	12q13	*IKZF4-RPS26*	A/G	0.83	0.81	1.14 (1.07-1.22)	1.5E-04	0.82	0.81	1.03 (0.97-1.10)	3.5E-01	0.81	0.80	1.06 (0.95-1.18)	3.2E-01	1.08 (1.03-1.12)	4.4E-04
rs4943253	13	34,245,598	13q13	*NBEA*	A/G	0.44	0.41	1.12 (1.07-1.18)	1.8E-05	0.42	0.41	1.04 (0.99-1.09)	1.4E-01	0.42	0.41	1.04 (0.95-1.14)	3.7E-01	1.07 (1.04-1.11)	3.0E-05
rs17103212	14	34,878,995	14q13	*PSMA6-NFKBIA*	C/T	0.90	0.88	1.22 (1.12-1.33)	1.5E-05	0.88	0.89	0.98 (0.91-1.06)	6.6E-01	0.88	0.87	1.11 (0.97-1.27)	1.2E-01	1.09 (1.03-1.14)	2.2E-03
rs3783637	14	54,417,868	14q22	*GCH1*	C/T	0.76	0.74	1.13 (1.07-1.20)	6.5E-05	0.76	0.75	1.05 (1.00-1.12)	6.9E-02	0.75	0.72	1.12 (1.02-1.23)	2.2E-02	1.10 (1.06-1.14)	2.0E-06
rs1957895	14	60,978,085	14q23	*PRKCH*	G/T	0.40	0.39	1.12 (1.06-1.18)	4.1E-05	0.41	0.40	1.08 (1.03-1.14)	1.5E-03	0.40	0.39	1.03 (0.94-1.12)	5.2E-01	1.09 (1.05-1.13)	3.6E-07
rs2841277	14	104,462,050	14q32	*PLD4*	T/C	0.72	0.69	1.11 (1.05-1.18)	2.8E-04	0.72	0.68	1.18 (1.12-1.25)	4.1E-09	0.72	0.69	1.19 (1.08-1.30)	4.2E-04	1.15 (1.11-1.19)	1.9E-14
rs961090	15	38,404,706	15q15	*PLCB2*	C/T	0.86	0.84	1.15 (1.07-1.24)	2.3E-04	0.85	0.84	1.07 (1.00-1.15)	4.3E-02	0.85	0.85	0.99 (0.88-1.11)	8.0E-01	1.09 (1.04-1.14)	2.4E-04
rs6496667	15	88,694,672	15q26	*ZNF774*	A/C	0.38	0.35	1.13 (1.07-1.19)	4.7E-05	0.38	0.36	1.08 (1.03-1.14)	1.9E-03	0.36	0.36	1.01 (0.92-1.11)	8.2E-01	1.09 (1.05-1.13)	1.4E-06
rs7498915	16	17,427,348	16p12	*XYLT1*	T/C	0.95	0.93	1.28 (1.14-1.44)	6.6E-05	0.93	0.92	1.07 (0.98-1.18)	1.5E-01	0.93	0.92	1.09 (0.92-1.28)	3.3E-01	1.14 (1.06-1.22)	1.6E-04
rs7404928	16	23,796,341	16p12	*PRKCB1*	T/C	0.65	0.62	1.13 (1.07-1.19)	1.5E-05	0.64	0.62	1.07 (1.01-1.12)	1.6E-02	0.64	0.64	1.01 (0.93-1.11)	7.9E-01	1.08 (1.05-1.12)	4.0E-06
rs2280381	16	84,576,134	16q24	*IRF8*	T/C	0.86	0.84	1.16 (1.08-1.25)	1.0E-04	0.85	0.83	1.10 (1.03-1.17)	7.0E-03	0.84	0.84	1.06 (0.94-1.19)	3.4E-01	1.12 (1.07-1.17)	2.4E-06
rs2290400	17	35,319,766	17q12	*IKZF3-ZPBP2-GSDML-ORMDL3 -GSDM1-PSMD3-CSF3*	C/T	0.28	0.26	1.12 (1.05-1.18)	2.8E-04	0.27	0.27	1.01 (0.96-1.07)	6.8E-01	0.30	0.27	1.13 (1.03-1.25)	1.1E-02	1.07 (1.03-1.11)	2.3E-04
rs9908256	17	40,406,871	17q21	*C1QL1*	C/T	0.59	0.57	1.11 (1.05-1.17)	1.8E-04	0.58	0.58	1.01 (0.96-1.07)	6.0E-01	0.56	0.58	0.92 (0.85-1.01)	7.6E-02	1.04 (1.00-1.07)	3.3E-02
rs4328484	17	66,627,825	17q24	no gene	A/G	0.65	0.62	1.13 (1.07-1.19)	1.3E-05	0.62	0.62	0.99 (0.94-1.04)	5.6E-01	0.62	0.62	1.00 (0.91-1.09)	9.6E-01	1.04 (1.01-1.08)	1.2E-02
rs2847297	18	12,787,694	18p11	*PTPN2*	G/A	0.37	0.33	1.16 (1.11-1.23)	3.5E-08	0.36	0.35	1.02 (0.97-1.08)	3.9E-01	0.39	0.35	1.17 (1.07-1.28)	5.0E-04	1.10 (1.07-1.14)	2.2E-08
rs1284427	18	13,620,634	18p11	*C18orf1*	G/A	0.52	0.49	1.11 (1.06-1.17)	8.7E-05	0.49	0.50	0.96 (0.92-1.01)	1.4E-01	0.51	0.51	1.00 (0.92-1.09)	9.8E-01	1.03 (1.00-1.06)	9.3E-02
rs12625311	20	51,270,200	20q13	*TSHZ2*	C/T	0.36	0.34	1.12 (1.06-1.18)	6.4E-05	0.33	0.34	0.95 (0.90-1.00)	5.1E-02	0.34	0.33	1.04 (0.95-1.13)	4.5E-01	1.03 (0.99-1.07)	9.8E-02

[a]Based on forward strand and NCBI Build 36.3. Selection criteria of the SNPs in the replication studies are described in **ONLINE METHODS**.

[b]Odds ratio of allele 1.

GWAS, genome-wide association study; RA, rheumatoid arthritis; OR, odds ratio; 95%CI, 95% confidence interval.

Supplementary Table 4. Results of cis-expression quantitative trait locus (cis-eQTL) analysis in the novel rheumatoid arthritis loci.

rsID[a]	Chr	Position (bp)	Cyto-band	Gene	No. cis-probes[b]	Smallest cis-eQTL P[c]	Corrected cis-eQTL P[d]	Cis-eQTL probe[e]	Cis-eQTL gene[e]
rs11900673	2	62,306,165	2p15	*B3GNT2*	3	0.29	0.88	-	-
rs2867461	4	79,732,239	4q21	*ANXA3*	4	0.20	0.82	-	-
rs657075	5	131,458,017	5q31	*CSF2*	11	7.2×10^{-4}	0.0079	GI_4758867-S	*P4HA2*
rs12529514	6	14,204,637	6p23	*CD83*	6	0.19	1	-	-
rs2233434	6	44,340,898	6p21.1	*NFKBIE*	14	0.0021	0.030	GI_38569416-S	*AARS2*
rs10821944	10	63,455,095	10q21	*ARID5B*	2	0.085	0.17	-	-
rs3781913	11	72,051,144	11q13	*PDE2A-ARAP1*	9	0.0032	0.029	GI_30157198-S	*STARD10*
rs2841277	14	104,462,050	14q32	*PLD4*	19	0.077	1	-	-
rs2847297	18	12,787,694	18p11	*PTPN2*	7	0.079	0.56	-	-

[a]Based on forward strand and NCBI Build 36.3.

[b]No. cis-probes located ± 300 kbp of the landmark SNP and previously measured in lymphoblastoid B cell lines obtained from HapMap Phase II East Asian populations (GSE6536)[1].

[c]The smallest *P*-value obtained from correlation analysis between SNP genotypes and expression levels of cis-probes.

[d]The smallest *P*-value obtained from correlation analysis after the application of Bonferroni correction based on the number of cis-probes.

[e]Cis-eQTL probes and corresponding genes which demonstrated significant associations after Bonferroni correction (corrected $P < 0.05$).

Supplementary Table 5. Associations of the identified loci with SLE and Graves' disease.

rsID[a]	Chr	Position (bp)	Cyto-band	Gene(s)	Allele 1/2	Associations with SLE					Associations with Graves' disease				
						Allele 1 Freq.					Allele 1 Freq.				
						Cases (n = 891)	Control (n = 3,384)	OR (95%CI)[b]	P	Power[c]	Cases (n = 1,783)	Control (n = 3,384)	OR (95%CI)[b]	P	Power[c]
rs11900673	2	62,306,165	2p15	*B3GNT2*	T/C	0.30	0.29	1.07 (0.96-1.20)	0.23	5.4%	0.32	0.29	1.17 (1.08-1.28)	3.5×10^{-4}	77.0%
rs2867461	4	79,732,239	4q21	*ANXA3*	A/G	0.48	0.44	1.17 (1.05-1.29)	0.0040	56.8%	0.47	0.44	1.12 (1.03-1.22)	0.0057	48.1%
rs657075	5	131,458,017	5q31	*CSF2*	A/G	0.37	0.36	1.05 (0.95-1.17)	0.33	3.0%	0.38	0.36	1.08 (0.99-1.18)	0.067	16.0%
rs12529514	6	14,204,637	6p23	*CD83*	C/T	0.16	0.15	1.11 (0.97-1.28)	0.13	9.1%	0.15	0.15	1.00 (0.89-1.12)	0.94	< 0.1%
rs10821944	10	63,455,095	10q21	*ARID5B*	G/T	0.39	0.36	1.11 (1.00-1.24)	0.052	19.2%	0.40	0.36	1.17 (1.08-1.27)	2.9×10^{-4}	82.0%
rs2233434	6	44,340,898	6p21.1	*NFKBIE*	G/A	0.22	0.22	1.04 (0.92-1.18)	0.51	1.6%	0.21	0.22	0.99 (0.90-1.09)	0.81	< 0.1%
rs3781913	11	72,051,144	11q13	*PDE2A-ARAP1*	T/G	0.70	0.69	1.04 (0.93-1.17)	0.48	1.9%	0.69	0.69	0.96 (0.88-1.05)	0.42	3.2%
rs2841277	14	104,462,050	14q32	*PLD4*	T/C	0.72	0.68	1.18 (1.05-1.32)	0.0057	52.0%	0.69	0.68	1.05 (0.96-1.15)	0.27	4.7%
rs2847297	18	12,787,694	18p11	*PTPN2*	G/A	0.36	0.35	1.06 (0.95-1.18)	0.33	4.3%	0.37	0.35	1.08 (0.99-1.17)	0.092	16.2%

[a]SNPs that satisfied $P < 5.0 \times 10^{-8}$ with rheumatoid arthritis in the combined study are indicated based on forward strand and NCBI Build 36.3.

[b]Odds ratio of allele 1.

[c]Estimated based on $\alpha = 0.05/9 = 0.0056$, number of the subjects in the cohort of SLE or Graves' disease, allele frequency in the controls, and odds ratio of the SNP obtained for SLE or Graves' disease, using Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/).

SLE, systemic lupus erythematosus; OR, odds ratio; 95%CI, 95% confidence interval.

Supplementary Table 6. Associations in the previously reported loci associated with rheumatoid arthritis.

rsID[a]	Chr	Position (bp)	Cyto-band	Gene(s)	Allele 1/2	GWAS meta-analysis in Japaneses				GWAS meta-analysis in Europeans[c]				Associations in[d]	
						Allele 1 Freq.		OR (95%CI)[b]	*P*	Allele 1 Freq.		OR (95%CI)[b]	*P*	Japanese	Europeans
						RA	Control			RA	Control				
rs3890745	1	2,585,786	1p36	*TNFRSF14*	T/C	0.54	0.51	1.11 (1.06-1.17)	6.8E-05	0.71	0.68	1.12 (1.06-1.18)	5.6E-06	+	+
rs766449	1	17,420,158	1p36	*PADI4*	T/C	0.44	0.40	1.17 (1.11-1.24)	4.6E-08	0.38	0.37	1.09 (1.03-1.15)	0.0022	++	+
rs2476601	1	114,089,610	1p13	*PTPN22*	A/G	0.00	0.00	NA		0.17	0.10	1.94 (1.80-2.09)	6.2E-71		++
rs11586238	1	116,975,180	1p13	*CD2-CD58*	G/C	0.042	0.042	0.94 (0.82-1.07)	0.35	0.26	0.23	1.13 (1.07-1.19)	1.5E-05		+
rs10430455	1	154,516,311	1q23	*FCRL3*	T/A	0.41	0.38	1.12 (1.06-1.18)	7.2E-05	0.47	0.45	1.08 (1.03-1.13)	9.0E-04	+	+
rs12746613	1	158,280,097	1q23	*FCGR2A*	T/C	0.00	0.00	NA		0.13	0.12	1.13 (1.05-1.21)	5.7E-04		+
rs6682654	1	159,075,627	1q23	*CD244*	G/A	0.63	0.62	1.05 (0.99-1.10)	0.087	0.44	0.43	1.02 (0.98-1.06)	0.37		
rs10919563	1	195,432,099	1q31	*PTPRC*	G/A	0.77	0.77	0.99 (0.93-1.05)	0.67	0.89	0.87	1.14 (1.06-1.22)	3.3E-04		+
rs13031237	2	61,047,780	2p16	*REL*	T/G	0.033	0.037	0.97 (0.84-1.13)	0.71	0.39	0.36	1.13 (1.08-1.19)	1.3E-06		+
rs11900673	2	62,364,312	2p15	*B3GNT2*	T/C	0.31	0.28	1.15 (1.08-1.21)	3.5E-06	0.13	0.13	1.05 (0.98-1.13)	0.17	+	
rs934734	2	65,507,237	2p14	*SPRED2*	G/A	0.19	0.16	1.19 (1.12-1.27)	3.2E-07	0.52	0.49	1.13 (1.08-1.19)	5.5E-07	+	+
rs11676922	2	100,265,458	2q11	*AFF3*	T/A	0.51	0.49	1.10 (1.04-1.16)	5.0E-04	0.49	0.46	1.12 (1.07-1.17)	1.1E-06	+	+
rs7574865	2	191,790,139	2q32	*STAT4*	T/G	0.36	0.33	1.16 (1.09-1.22)	8.9E-07	0.25	0.22	1.16 (1.09-1.23)	4.9E-07	+	+
rs1980422	2	204,435,902	2q33	*CD28*	C/T	0.063	0.068	0.92 (0.64-1.34)	0.67	0.26	0.24	1.12 (1.06-1.18)	7.4E-05		+
rs3087243	2	204,564,425	2q33	*CTLA4*	G/A	0.75	0.73	1.10 (1.04-1.16)	0.0023	0.61	0.56	1.15 (1.10-1.20)	2.2E-08	+	++
rs13315591	3	58,531,881	3p14	*PXK*	C/T	0.00	0.00	NA		0.10	0.086	1.29 (1.17-1.43)	6.3E-07		+
rs874040	4	25,784,466	4p15	*RBPJ*	C/G	0.00	0.00	NA		0.33	0.30	1.14 (1.08-1.20)	3.3E-07		+
rs2867461	4	79,870,394	4q21	*ANXA3*	A/G	0.46	0.44	1.13 (1.08-1.19)	4.7E-06	0.37	0.37	0.98 (0.92-1.04)	0.52	+	
rs6822844	4	123,867,026	4q27	*IL2-IL21*	G/T	1.00	1.00	NA		0.84	0.82	1.11 (1.04-1.18)	8.3E-04		+
rs6859219	5	55,474,337	5q11	*ANKRD55-IL6ST*	C/A	0.98	0.97	1.26 (1.00-1.59)	0.044	0.82	0.79	1.28 (1.18-1.39)	5.1E-09		++
rs26232	5	102,624,619	5q21	*C5orf30*	C/T	0.73	0.72	1.01 (0.95-1.07)	0.75	0.71	0.68	1.14 (1.08-1.19)	7.3E-07		+
rs657075	5	131,458,017	5q31	*CSF2*	A/G	0.38	0.36	1.12 (1.06-1.18)	3.2E-05	0.10	0.10	1.04 (0.95-1.13)	0.37	+	
rs12529514	6	14,204,637	6p23	*CD83*	C/T	0.16	0.14	1.19 (1.10-1.27)	6.8E-06	0.055	0.053	1.11 (0.99-1.24)	0.074	+	
rs2157337	6	32,609,122	6p21.3	*HLA-DRB1*	C/T	0.59	0.44	1.99 (1.88-2.11)	2.6E-118	0.69	0.46	2.50 (2.39-2.62)	< 10E-300	++	++
rs2233434	6	44,340,898	6p21.1	*NFKBIE*	G/A	0.24	0.21	1.23 (1.16-1.31)	9.2E-11	0.059	0.040	1.57 (1.11-2.21)	0.0099	++	
rs548234	6	106,674,727	6q21	*PRDM1*	C/T	0.34	0.33	1.02 (0.97-1.08)	0.41	0.34	0.33	1.10 (1.05-1.16)	1.3E-04		+
rs5029937	6	138,236,844	6q23	*TNFAIP3*	T/G	0.089	0.068	1.33 (1.21-1.45)	3.9E-09	0.046	0.036	1.40 (1.24-1.59)	1.4E-07	++	+
rs394581	6	159,452,930	6q25	*TAGAP*	T/C	0.98	0.97	1.23 (1.04-1.46)	0.022	0.73	0.70	1.10 (1.04-1.16)	7.7E-04		+
rs3093023	6	167,504,701	6q27	*CCR6*	A/G	0.52	0.46	1.27 (1.20-1.34)	2.1E-17	0.47	0.43	1.13 (1.08-1.19)	5.7E-07	++	+
rs10488631	7	128,188,134	7q32	*IRF5*[e]	C/T	0.00	0.00	NA		0.13	0.11	1.19 (1.10-1.28)	4.3E-06	+	+
rs13225818	7	128,329,965			T/C	0.88	0.86	1.23 (1.14-1.33)	4.0E-07	0.83	0.85	0.93 (0.87-0.99)	0.022		
rs2736340	8	11,381,382	8p23	*BLK*	T/C	0.72	0.69	1.12 (1.06-1.18)	1.2E-04	0.27	0.25	1.12 (1.06-1.18)	2.2E-05	+	+
rs951005	9	34,733,681	9p13	*CCL21*	A/G	0.98	0.98	1.08 (0.88-1.32)	0.45	0.86	0.84	1.19 (1.11-1.28)	9.1E-07		+
rs3761847	9	120,769,793	9q33	*TRAF1-C5*	G/A	0.53	0.52	1.06 (1.01-1.12)	0.025	0.46	0.43	1.13 (1.08-1.18)	3.7E-07		+
rs706778	10	6,138,955	10p15	*IL2RA*	T/C	0.57	0.56	1.02 (0.96-1.07)	0.55	0.44	0.41	1.14 (1.09-1.20)	1.4E-07		+
rs4750316	10	6,433,266	10p15	*PRKCQ*	G/C	0.88	0.88	1.00 (0.92-1.08)	0.92	0.83	0.81	1.15 (1.09-1.22)	3.2E-06		+
rs10821944	10	63,455,095	10q21	*ARID5B*	G/T	0.39	0.36	1.17 (1.11-1.23)	1.0E-08	0.29	0.26	1.11 (1.05-1.17)	1.9E-04	++	+
rs540386	11	36,481,869	11p12	*TRAF6*	C/T	0.97	0.97	1.09 (0.88-1.35)	0.45	0.87	0.86	1.14 (1.06-1.22)	3.8E-04		+
rs3781913	11	72,051,144	11q13	*PDE2A-ARAP1*	T/G	0.71	0.69	1.11 (1.05-1.17)	3.2E-04	0.45	0.43	1.04 (0.99-1.09)	0.13	+	
rs10892279	11	118,116,991	11q23	*DDX6*	G/A	0.81	0.80	1.08 (1.01-1.15)	0.030	0.82	0.80	1.15 (1.09-1.22)	5.8E-06		+
rs1678542	12	56,254,982	12q13	*KIF5A-PIP4K2C*	C/G	0.21	0.20	1.05 (0.98-1.11)	0.18	0.64	0.62	1.10 (1.04-1.15)	2.3E-04		+
rs2841277	14	104,462,050	14q32	*PLD4*	T/C	0.72	0.69	1.11 (1.05-1.18)	2.8E-04	0.47	0.46	1.02 (0.96-1.09)	0.54	+	
rs2847297	18	12,787,694	18p11	*PTPN2*	G/A	0.37	0.33	1.16 (1.11-1.23)	3.5E-08	0.36	0.34	1.10 (1.05-1.15)	9.2E-05	++	+
rs4810485	20	44,181,354	20q13	*CD40*	G/T	0.63	0.61	1.08 (1.02-1.14)	0.0054	0.78	0.75	1.18 (1.11-1.25)	5.7E-09		++
rs2075876	21	44,533,581	21q22	*AIRE*	A/G	0.38	0.35	1.14 (1.08-1.20)	2.8E-06	0.12	0.12	1.00 (0.93-1.08)	0.94	+	
rs3218253	22	35,869,310	22q12	*IL2RB*	A/G	0.072	0.071	0.99 (0.90-1.10)	0.88	0.28	0.26	1.09 (1.03-1.15)	0.0027		+

[a]Based on forward strand and NCBI Build 36.3. The risk allele for rheumatoid arthritis in the previously reported studies[2-19] was denoted as allele 1.

[b]Odds ratio of allele 1.

[c]Associations in the previous meta-analysis in the European populations are referenced[15].

[d]*P*-value that satisfied genome-wide significance threshold ($P < 5.0 \times 10^{-8}$) and false discovery rate (FDR) < 0.05 ($5.0 \times 10^{-8} \leq P < 0.0030$) are indicated as "++" and "+", respectively.

[e]In the *IRF5* locus, different causal variants were reported for the Japanese and European populations[15,20].

GWAS, genome-wide association study; RA, rheumatoid arthritis; OR, odds ratio; 95%CI, 95% confidence interval; NA, not available.